- Home
- INCY vs AS Comparison
INCY vs AS Comparison
Compare INCY & AS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- AS
- Stock Information
- Founded
- INCY 1991
- AS 1950
- Country
- INCY United States
- AS Finland
- Employees
- INCY N/A
- AS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- AS
- Sector
- INCY Health Care
- AS
- Exchange
- INCY Nasdaq
- AS NYSE
- Market Cap
- INCY 13.4B
- AS 13.3B
- IPO Year
- INCY 1993
- AS 2024
- Fundamental
- Price
- INCY $68.07
- AS $26.75
- Analyst Decision
- INCY Buy
- AS Buy
- Analyst Count
- INCY 19
- AS 11
- Target Price
- INCY $74.38
- AS $30.18
- AVG Volume (30 Days)
- INCY 1.8M
- AS 4.2M
- Earning Date
- INCY 04-29-2025
- AS 02-25-2025
- Dividend Yield
- INCY N/A
- AS N/A
- EPS Growth
- INCY N/A
- AS N/A
- EPS
- INCY 0.15
- AS 0.14
- Revenue
- INCY $4,241,216,999.00
- AS $5,183,300,000.00
- Revenue This Year
- INCY $12.23
- AS $18.17
- Revenue Next Year
- INCY $8.89
- AS $13.19
- P/E Ratio
- INCY $454.93
- AS $182.86
- Revenue Growth
- INCY 14.76
- AS 18.65
- 52 Week Low
- INCY $50.35
- AS $10.11
- 52 Week High
- INCY $83.95
- AS $34.00
- Technical
- Relative Strength Index (RSI)
- INCY 38.27
- AS 39.71
- Support Level
- INCY $68.17
- AS $25.04
- Resistance Level
- INCY $72.81
- AS $29.83
- Average True Range (ATR)
- INCY 2.29
- AS 1.76
- MACD
- INCY -0.32
- AS -0.40
- Stochastic Oscillator
- INCY 8.61
- AS 26.67
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About AS AMER SPORTS INC
Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.